ALAYNA SIZEMORE: Open Payments
NPI 1144943119 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,185 in 170 payments from 34 companies in 2025. Trend: 2023 $3,688 · 2024 $6,191 · 2025 $4,185
Food & beverage: $3,998Consulting: $175Education: $12
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $643 |
| Alexion Pharmaceuticals, Inc. | 6 | $402 |
| Janssen Biotech, Inc. | 5 | $289 |
| Vanda Pharmaceuticals Inc. | 17 | $234 |
| TG Therapeutics, Inc. | 6 | $210 |
| UCB, Inc. | 9 | $191 |
| Genentech USA, Inc. | 5 | $187 |
| Neurocrine BioSciences, Inc. | 4 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $168 |
| CSL Behring | 4 | $167 |
Products named: QULIPTA, ULTOMIRIS, PONVORY, BRIUMVI, UBRELVY, INGREZZA, HYQVIA, Hizentra.
Industry payments across MD — which companies pay providers there.
